| ²é¿´: 1388 | »Ø¸´: 2 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
lsysxhÌú¸Ëľ³æ (ÖøÃûдÊÖ)
ÌǺù«
|
[ÇóÖú]
·Òë¼±Óã¬Ò»¹²Æß¾ä»°£¡£¡30½ð±Ò·îÉÏ£¬·ÒëµÄºÃ¿É×·¼Ó£¡
|
||
|
Advanced microscopy solutions for monitoring the kinetics and dynamics of drug¨CDNA targeting in living cells Abstract Many anticancer drugs require interaction with DNA or chromatin components of tumor cells to achieve therapeutic activity. Quantification and exploration of drug targeting dynamics can be highly informative in the rational development of new therapies and in the drug discovery pipeline. The problems faced include the potential infrequency and transient nature of critical events, the influence of micropharmacokinetics on the drug¨Ctarget equilibria, the dependence on preserving cell function to demonstrate dynamic processes in situ, the need to map events in functional cells and the confounding effects of cell-to-cell heterogeneity. We demonstrate technological solutions in which we have integrated two-photon laser scanning microscopy (TPLSM) to track drug delivery in subcellular compartments, with the mapping of sites of critical molecular interactions. We address key design concepts for the development of modular tools used to uncover the complexity of drug targeting in single cells. First, we describe the combination of two-photon excitation with fluorescence lifetime imaging microscopy (FLIM) to map the nuclear docking of the anticancer drug topotecan (TPT) at a subset of DNA sites in nuclear structures of live breast tumor cells. Secondly, we demonstrate how we incorporate the smart design of a two-photon ¡°dark¡± DNA binding probe, such as DRAQ5, as a well-defined quenching probe to uncover sites of drug interaction. Finally, we discuss the future perspectives on introducing these modular kinetic assays in the high-content screening arena and the interlinking of the consequences of drug¨Ctarget interactions with cellular stress responses. |
» ²ÂÄãϲ»¶
277µ÷¼Á
ÒѾÓÐ6È˻ظ´
341Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑоÀú
ÒѾÓÐ8È˻ظ´
293Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
070300»¯Ñ§319Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
268Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0703»¯Ñ§336·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶306Ó¢Ò»Êý¶þ
ÒѾÓÐ9È˻ظ´
yuanbing0000
ÖÁ×ðľ³æ (СÓÐÃûÆø)
- ·ÒëEPI: 21
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 13187.7
- ºì»¨: 1
- Ìû×Ó: 81
- ÔÚÏß: 70.3Сʱ
- ³æºÅ: 1143224
- ×¢²á: 2010-11-10
- ÐÔ±ð: MM
- רҵ: ´«¶¯»úеѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
Mally89(½ð±Ò+1): ¸ÐлӦÖú£¡~»¶Ó³£À´£¡~ºðºð£¡~\(^o^)/~ 2012-03-05 13:57:24
lsysxh(½ð±Ò+30, ·ÒëEPI+1): ¡ï¡ï¡ïºÜÓаïÖú Ì«¸ÐлÄãÁË£¬Õ⼸Ìì³îµÄÀ÷º¦°¡ 2012-03-06 13:55:10
Mally89(½ð±Ò+1): ¸ÐлӦÖú£¡~»¶Ó³£À´£¡~ºðºð£¡~\(^o^)/~ 2012-03-05 13:57:24
lsysxh(½ð±Ò+30, ·ÒëEPI+1): ¡ï¡ï¡ïºÜÓаïÖú Ì«¸ÐлÄãÁË£¬Õ⼸Ìì³îµÄÀ÷º¦°¡ 2012-03-06 13:55:10
|
¶Ô¸Ãרҵ±³¾°ÓëÊõÓï²»ÉõÁ˽⣬ÒÔÏÂÄÚÈݽö¹©²Î¿¼: ÒÔ»îÌåϸ°ûΪĿ±êÓÃÏȽøµÄÏÔ΢¾µ·½·¨¼à¿ØÒ©ÎïºÍDNAÖ®¼äµÄ¶¯Á¦Ñ§ ÕªÒª: ºÜ¶à¿¹°©Ò©ÎïÐèÒªÓëDNA»òÖ×Áöϸ°ûµÄȾɫÖʳɷÖÏ໥×÷ÓÃÒÔÍê³ÉÖÎÁÆ¡£ÒÔ¶¯Á¦Ñ§ÎªÄ¿±ê¶ÔÒ©Îï½øÐÐÁ¿»¯ºÍÑо¿ÄܶÔÐÂÖÎÁÆ·½·¨µÄºÏÀí·¢Õ¹¼°Ò©Îï·¢ÏÖ;¾¶·½ÃæÌṩ´óÁ¿×ÊÁÏ¡£ÃæÁÙµÄÎÊÌâ°üÀ¨ÁÙ½çʼþ²»¶à¼ûÐÔ¼°Ë²Ê±ÐÔ£¬Î¢¹ÛÒ©Îï´úл¶¯Á¦Ñ§¶Ô¾ùºâÒ©ÎïÓëÄ¿±êµÄÓ°Ï죬Ϊ֤Ã÷¶¯Ì¬×÷ÓöԱ£³Öϸ°û¹¦ÄܵÄÒÀÀµ£¬ÐèÒª»æÖÆ»úÄÜϸ°û»î¶¯¼°Ï¸°û¶Ôϸ°ûÒìÖÊÐԵĻìºÏЧӦ¡£ÎÒÃÇÑÝʾÁËË«¹â×Ó¼¤¹â¼¯³ÉɨÃèÏÔ΢¾µ·¨ÒÔ×·×ÙÒ©ÎïÔÚÑÇϸ°û¿Õ¼äµÄ´«Ë͵ļ¼Êõ·½·¨£¬¸ø³öÁËÁÙ½ç·Ö×ÓÏ໥×÷ÓÃλÖÃͼ¡£ÒÔµ¥Ï¸°ûΪ¶ÔÏó£¬Îª½ÒʾҩÎïµÄ¸´ÔÓÐÔ£¬ÎÒÃÇΪģ¿é»¯¹¤¾ßµÄ·¢Õ¹Ìá³öÖØÒªµÄÉè¼ÆÀíÄî¡£Ê×ÏÈ£¬¼Ç¼˫¹â×Ó¼¤¸ÐÓë³ÉÏñÏÔ΢¾µÓ«¹âÊÙÃüµÄ×éºÏ£¬»æÖÆ¿¹°©Ò©ÎïTPTÔÚ»îÌåÐØ²¿Ö×Áöϸ°ûºËÐĽṹÖÐDNA³¡×Ó¼¯µÄºËÐÄ´æ·Å´¦£»Æä´Î£¬ËµÃ÷ÎÒÃÇÔõÑùʹ˫¹â×ÓÄ£ºýÔ¼ÊøÌ½ÕëµÄ¾«È·Éè¼Æ¾ßÌ廯£¬±ÈÈçDRAQ5£¬×÷Ϊ¶¨ÒåÃ÷È·µÄ´ã»ð̽Õë½ÒʾҩÎïÏ໥×÷Óõij¡Ëù£»×îºó£¬ÌÖÂÛ¹ØÓÚÒý½øÕâЩģ¿é»¯·ÖÎöÔÚ¸ßÂúÒâ¶ÈµÄÆÁ±ÎÁìÓòδÀ´µÄǰ¾°¼°Ò©Îï-Ä¿±êÓëϸ°ûÓ¦Á¦Ï໥×÷Óýá¹ûµÄÄÚ²¿ÁªÏµ. |
2Â¥2012-03-04 22:58:27
dc121
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 7551.2
- É¢½ð: 337
- ºì»¨: 5
- Ìû×Ó: 2379
- ÔÚÏß: 458.3Сʱ
- ³æºÅ: 1446107
- ×¢²á: 2011-10-16
- ÐÔ±ð: GG
- רҵ: Âí¿Ë˼Ö÷Òå

3Â¥2012-03-05 19:53:26













»Ø¸´´ËÂ¥

5